Drug Profile
PAC 113
Alternative Names: P 113L; PAC-113; PAC-113 Mouth RinseLatest Information Update: 16 Apr 2021
Price :
$50
*
At a glance
- Originator Demegen
- Developer Demegen; General Biologicals Corporation; Pacgen Life Science Corporation
- Class Antibacterials; Antifungals; Peptide antibiotics; Peptides
- Mechanism of Action Cell membrane permeability enhancers; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Candidiasis
- Discontinued Gingivitis; Mucositis
Most Recent Events
- 16 Apr 2021 PAC 113 is still in phase II trial for Candidiasis in Taiwan (Pacgen Life Sciences pipeline)
- 22 Jul 2016 Phase-II clinical trials in Candidiasis in Taiwan (PO) before July 2016
- 24 Jan 2014 Pacgen Life Science enter into a sublicensing agreement with General Biological Corporation for PAC 113 for any oral condition (excluding transitional skin-mucous membrane areas) and also for vaginal, dermatological and ophthalmic conditions